Literature DB >> 3913603

Biobehavioral sequellae associated with adrenergic-inhibiting antihypertensive agents: a critical review.

R C Rosen, J B Kostis.   

Abstract

Adrenergic-inhibiting antihypertensive drugs, most notably the beta-blockers and alpha-agonists, have been shown to influence a variety of central nervous system (CNS) functions. In some instances the use of these drugs has also been reported to lead to serious psychiatric complications. Despite the clinical significance of these effects and the potential threat to treatment adherence the underlying mechanisms are poorly understood. This article critically evaluates the existing research in six major areas: (a) depression, (b) lethargy/fatigue, (c) cognitive and perceptual-motor performance, (d) quantitative electroencephalogram (EEG) changes, (e) sleep, and (f) sexual function. In general, the evidence suggests that a pseudo-depressive state may be a relatively common side effect of treatment, and that associated changes in cognitive, affective, sleep, and sexual function may be frequently encountered.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3913603     DOI: 10.1037//0278-6133.4.6.579

Source DB:  PubMed          Journal:  Health Psychol        ISSN: 0278-6133            Impact factor:   4.267


  10 in total

1.  Subjective symptoms and pharmacokinetics/dynamics of metoprolol CR in elderly subjects--a comparison with atenolol.

Authors:  E S Dimenäs; C G Dahlöf; B Heibel; R G Moore; B K Olofsson; G E Westergren; P W Lücker
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

Review 2.  Autonomic activation in insomnia: the case for acupuncture.

Authors:  Wei Huang; Nancy Kutner; Donald L Bliwise
Journal:  J Clin Sleep Med       Date:  2011-02-15       Impact factor: 4.062

3.  CNS-related subjective symptoms during treatment with beta 1-adrenoceptor antagonists (atenolol, metoprolol): two double-blind placebo controlled studies.

Authors:  E Dimenäs; C Dahlöf; B Olofsson; I Wiklund
Journal:  Br J Clin Pharmacol       Date:  1989-11       Impact factor: 4.335

4.  Documentation of an instrument for assessment of subjective CNS-related symptoms during cardiovascular pharmacotherapy.

Authors:  C Dahlöf; E Dimenäs; B Olofsson
Journal:  Cardiovasc Drugs Ther       Date:  1989-12       Impact factor: 3.727

5.  A controlled comparison of thermal biofeedback and relaxation training in the treatment of essential hypertension: III. Psychological changes accompanying treatment.

Authors:  E B Blanchard; R J McCaffrey; A Musso; M A Gerardi; G C McCoy
Journal:  Biofeedback Self Regul       Date:  1987-09

6.  β1-adrenergic receptors mediate plasma acyl-ghrelin elevation and depressive-like behavior induced by chronic psychosocial stress.

Authors:  Deepali Gupta; Jen-Chieh Chuang; Bharath K Mani; Kripa Shankar; Juan A Rodriguez; Sherri Osborne-Lawrence; Nathan P Metzger; Jeffrey M Zigman
Journal:  Neuropsychopharmacology       Date:  2019-02-08       Impact factor: 7.853

Review 7.  Quality of life as a therapeutic end-point. An analysis of therapeutic trials in hypertension.

Authors:  N K Hollenberg; M Testa; G H Williams
Journal:  Drug Saf       Date:  1991 Mar-Apr       Impact factor: 5.606

8.  CNS side effects of centrally-active antihypertensive agents: a prospective, placebo-controlled study of sleep, mood state, and cognitive and sexual function in hypertensive males.

Authors:  J B Kostis; R C Rosen; B C Holzer; C Randolph; L S Taska; M H Miller
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

9.  Sexual sequelae of antihypertensive drugs: treatment effects on self-report and physiological measures in middle-aged male hypertensives.

Authors:  R C Rosen; J B Kostis; A Jekelis; L S Taska
Journal:  Arch Sex Behav       Date:  1994-04

Review 10.  Neuropsychiatric consequences of cardiovascular medications.

Authors:  Jeff C Huffman; Theodore A Stern
Journal:  Dialogues Clin Neurosci       Date:  2007       Impact factor: 5.986

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.